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17 One Sentence Summary: High intensity focused ultrasound can ablate blood flow in the sheep 
 
18 placenta and is potentially translatable to human twin twin-transfusion syndrome, where the 
 
19 invasive nature of current treatments limit their value. 
 
20 
 
 
 
 
 
 
 
 
21 Abstract: 
 
22 Aims: We investigated the efficacy, materno-fetal responses and safety of using high intensity 
 
23 focused ultrasound (HIFU) to non-invasively occlude placental vasculature compared to sham 
 
24 treatment in anaesthetised pregnant sheep. A technique for non-invasive occlusion of placental 
 
25 vasculature may be translatable to the treatment of conditions arising from abnormal placental 
 
26 vasculature, such as Twin Twin Transfusion Syndrome (TTTS). 
 
27 Methods: Eleven sheep were instrumented and exposed to HIFU (n=5) or sham (n=6) ablation 
 
28 of placental vasculature through the exposed uterine surface. 
 
29 Results: Placental vascular flow was occluded in 28/30 targets and histological examination 
 
30 confirmed occlusion in 24/30. In both HIFU and sham exposures, uterine contact reduced 
 
31 maternal uterine artery flow but delivery of oxygen and glucose to the fetal brain remained 
 
32 normal. 
 
33 Conclusion: HIFU can occlude in vivo placental vasculature and ablate blood flow consistently 
 
34 in a pregnant sheep model. Cardiovascular and metabolic fetal responses suggest that the 
 
35 technique is safe in the short-term, and potentially translatable to human pregnancy. 
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37 Introduction 
 
38 High intensity focused ultrasound (HIFU) (1) is a clinically approved therapeutic 
 
39 technique for non-invasive ablation of uterine fibroids, bony and soft tissue cancers . Ultrasound 
 
40 waves generated by a shaped piezoelectric ceramic transducer, positioned outside the body, 
 
41 produce localised tissue destruction at depth, using a combination of thermal and/or pressure 
 
42 effects (2). Converging ultrasound waves pass through overlying tissue, causing damage where 
 
43 energy is focused, to create a small lesion, (typically ellipsoidal, 1-2 mm in diameter and 8-15 
 
44 mm in length). Combined with diagnostic imaging to target the focus, lesions can be placed 
 
45 adjacent to each-other to destroy larger volumes of tissue. HIFU’s first in-human use in fetal 
 
46 medicine has been described: HIFU soft tissue ablation of the cord insertion in a compromised 
 
47 fetus with twin reversed arterial perfusion (TRAP) sequence afforded a better prognosis for the 
 
48 surviving twin (3); there are currently no other reports of HIFU use in human pregnancy. 
 
49 Twin-Twin Transfusion syndrome (TTTS) affects 10-15% (4) of monochorionic 
 
50 diamniotic (MCDA) twins, has an untreated mortality >80% (5) and is the leading cause of death 
 
51 and disability in twins (6). It results from abnormal vascular connections (predominantly arterio- 
 
52 venous anastomoses-AVAs) in monochorionic placentae which allow unequal sharing of 
 
53 placental blood flow (7). Treatment to divide the twin’s circulations is recommended in severe 
 
54 (stage 3-4) TTTS (8), where fetal compromise has already occurred (9). 
 
55 Fetoscopic laser occlusion of placental anastomoses to divide the fetal circulations has 
 
56 been developed over the last 20 years (10). Although neurological outcomes at 2 years may be 
 
57 improved, meta-analysis has not shown an improvement in survival (11). Complications are 
 
58 secondary to the invasive nature of the procedure as fetoscopy alone is recognised to worsen 
 
59 neonatal outcomes (9, 12-14); this limits the use of fetoscopic laser to cases of TTTS where fetal  
 
 
 
 
 
 
 
 
60 compromise has already occurred. AVAs typically lie deep within the placenta (15) but laser 
 
61 ablation is limited to a maximum depth of a few millimetres; residual anastomoses are visualised 
 
62 using colour Doppler in 15-30% cases (16). This may result in recurrent disease (17) or a related 
 
63 condition, twin anaemia-polycythaemia sequence (TAPS) which is three times more common 
 
64 after laser treatment (13). A non-invasive treatment which could divide placental circulations 
 
65 and occlude superficial or deep anastomoses could potentially reduce both procedure-related 
 
66 complications and incomplete vascular occlusion, offering a more effective treatment, whilst 
 
67 widening the scope of treatment. The use of HIFU to specifically occlude placental vasculature 
 
68 is a new application of the technology. 
 
69 As a precursor to human clinical trials, the aim of this study was to test the efficacy, 
 
70 feasibility and fetal-maternal safety of ultrasound guided HIFU placental vascular occlusion in a 
 
71 pregnant animal model. This study requires a model of placental vascular anastomoses: AVAs 
 
72 are 0.3-0.6 mm in diameter, veno-venous anastomoses may be up to 3.5 mm in diameter (18) 
 
73 The pregnant sheep cannot provide a true model of TTTS, as vascular anastomoses between 
 
74 allantoic circulations in multiple pregnancy in sheep are rare (19), unlike in human 
 
75 monochorionic placentation where they occur in 90% of cases (20).. Unlike the discoid human 
 
76 placenta, the sheep placenta is organised into discrete regions of maternal and fetal tissue called 
 
77 placentomes, regions of enmeshed maternal and fetal villi, where materno-fetal counter current 
 
78 flow and haemotrophic exchange takes place (21). Fetal vessels arise from placentomes and are 
 
79 up to 5mm in diameter and run between placentomes before joining together to form the  
 
80 umbilical cord, providing an appropriately sized target vessels. 
 
81 In the human placenta, fetal cotyledons are recognised, with discrete villous trees of fetal 
 
82 blood flow where concurrent flow and haemotrophic materno-fetal exchange occurs, despite the  
 
 
 
 
 
 
 
 
83 externally continuous nature of the placental surface. The villous trees of both human and sheep 
 
84 placentae are similar in that they contain stem, intermediate and terminal villi of comparable 
 
85 structure and size (22).  Hence, while the presentation of the human and sheep placentae 
 
86 initially appear very different, they are functionally comparable and their vasculature is 
 
87 anatomically similar, and the sheep has previously been used to demonstrate intrauterine 
 
88 fetoscopic laser ablation of placental vasculature (23). 
 
89 Unlike other experimental animal models, sheep tend to have singleton or twin 
 
90 pregnancies and the birth weight of the lamb is similar to that of the human baby. Furthermore, 
 
91 sheep and humans have comparable anatomy of the heart and vasculature, and the temporal 
 
92 development of the cardiovascular system is similar (24). The gestational time for the ewe is 
 
93 145-150 days, around 50% of the human gestational period, but longer than many other 
 
94 experimental animals, meaning that techniques, timing and duration of experimentation are more 
 
95 easily translated from a research to a clinical context.  
 
96 
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98 Results  
 
99 Efficacy and safety of HIFU placental vascular occlusion 
 
100 Based on comparison of pre- and post-exposure colour Doppler imaging, HIFU 
 
101 successfully ablated blood flow in 28 of 30 (93.3%) placental vesssels (fig. 1a,b). Of the 28 
 
102 successful ablations, 27 were achieved in a single exposure series; 2 of the 3 remaining 
 
103 placentomes were re-exposed which resulted in 1 further successful ablation (total 32 exposure 
 
104 series). During exposures, hyperechoic regions (fig. 1c) were seen to develop at the HIFU focus 
 
105 with harmonic imaging. The appearance of two or more successive hyperechoes in an exposure 
 
106 series was associated with successful ablation of blood flow in 28 of 28 successful HIFU 
 
107 exposure series and 0 of 4 unsuccessful ones. This was a more sensitive marker for monitoring 
 
108 treatment with harmonic imaging than placentome structural change, which was only seen in 15 
 
109 of 28 successful ablations. 
 
110 Treatment success was assessed using 3 measures. The primary measure was new onset 
 
111 absence of flow on colour Doppler following exposures (“no flow”), as this is the measure 
 
112 available clinically to judge success and guide therapy. The study design allowed secondary 
 
113 confirmation to be sought from macroscopic observation and histological examination of 
 
114 damaged tissue in the targeted region. As already described, treatment success defined by “no 
 
115 flow” was 93.3%. 
 
116 Gross pathological changes after HIFU exposure were observed macroscopically in the 
 
117 central region of all 30 targeted placentomes, either tissue darkening (fig. 2a) or tissue pallor (fig. 
 
118 2b), in some cases extending into the peripheries. This included the 2 in which flow was not 
 
119 successfully occluded. Histological examination of damaged tissue was possible in 26 of 30 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
120 placentomes; in 2 placentomes (<2 cm diameter) there was predominantly damaged tissue, 
 
121 rendering them too friable to be sectioned for H&E staining. In the remaining 2 placentomes 
 
122 there was no clear view of the origin of fetal vessels could be seen in the sections. Evidence of 
 
123 clot within fetal vessels, suggestive of occlusion, was found in 24/26 (92.3%) specimens and was 
 
124 not found in 2/26 (8.7%) or sham treated placentomes (fig 2c,d). The 2 placentomes without  
 
125 evidence of vessel occlusion where the same 2 in which colour flow Doppler signals were still 
 
126 present on the post treatment images. Outcomes are summarised in table S1. 
 
127 A single case of vessel hemorrhage in the 30 placentomes targeted (3.3%) was associated with  
 
128 equipment malfunction. The automated gantry failed to move and delivered four exposures to  
 
129 the same position in the vessel wall. We were not able to resolve the hemorrhage noninvasively,  
 
130 but all fetuses survived the experimental protocol despite this one incident. No damage to the  
 
131 uterus, adjacent maternal structure, or fetus was observed in this study, based on external exam- 
 
132 ination at postmortem 
 
 
 
 
 
 
134 Maternal cardiovascular, acid-base and metabolic responses to HIFU exposures 
 
135 In both HIFU and sham ablation studies, there was a reduction in uterine artery blood 
 
136 flow by up to 30% of basal flow, secondary to increased uterine artery vascular resistance during 
 
137 the period during the time the HIFU and sham exposures were being applied; the maternal mean 
 
138 arterial blood pressure and heart rate remained unchanged throughout the procedure (fig. 3). 
 
139 Given the reduction in blood flow had a similar time of onset and magnitude in both HIFU and 
 
140 sham ablations, the only common potentially causative event which occurred in both groups at 
 
141 this point in the experiment was the gentle handling and manipulation of the uterus to optimise 
 
142 the acoustic window. B-Mode/Doppler ultrasound was used during both the baseline and 
 
 
 
 
 
 
 
 
 
 
143 treatment phases of the experimental protocol so is unlikely to be the causative factor. Values 
 
144 for metabolic and acid-base status were not different between treatment groups at the start of 
 
145 baseline and remained predominantly unchanged during the experimental procedures involing 
 
146 both sham and HIFU exposures (table 1).  
 
147 
 
148 Fetal cardiovascular, acid-base and metabolic responses to HIFU exposures 
 
149 The fetal heart rate and mean arterial blood pressure remained constant throughout the 
 
150 experimental procedure (fig. 4). Blood flow to the fetal brain was unchanged in terms of 
 
151 absolute volume, and oxygen and glucose delivery to the fetal brain both remained within 
 
152 expected parameters, and were unaltered during the experimental procedure, despite a reduced 
 
153 partial pressure of oxygen (PaO2) in the fetal blood by the end of the recovery period. (fig. 4, 
 
154 tables 2,3). By the end of the recovery period, there was a gradual deterioration of fetal acid- 
 
155 base and metabolic status, which was not different in HIFU compared to sham groups, and 
 
156 changes occurred at the same time-points for both (table 2). 
 
157 There was a reduction in fetal femoral artery blood flow volume and an increase in 
 
158 femoral artery vascular resistance, which occurred in conjunction with the reduction in  
 
159 matenal uterine artery blood flow (figs. 3,4). There was also an increase in the ratio of blood  
 
160 flow between the fetal carotid and femoral arteries (fig. 4). 
 
161 The median duration of anaesthesia at the start of the experimental protocol (start of 
 
162 baseline recording) was 145 min (range 128-180 min) in the sham group and 138 min (range 
 
163 125-157 min) in the HIFU group. This was not significantly different (p=0.14) and values for 
 
164 maternal and fetal cardiovascular, metabolic and acid-base status during baseline recordings  
 165 were not different between exposed and sham groups, demonstrating that this difference in 
 
166 anaesthesia time was not clinically important. 
 
167 
 
168 
 
 
 
 
 
 
 
 
169 Discussion 
 
170 This study demonstrates the potential for the use of HIFU as a non-invasive method of 
 
171 placental vascular occlusion in pregnant sheep, an animal model that mimics vascular 
 
172 anastomoses in the monochorionic human placenta. The primary aims of this study were to 
 
173 assess the efficacy and safety of this technique for the mother and fetus. To this end, the 
 
174 recorded maternal and fetal cardiovascular, acid-base and metabolic responses secondary to 
 
175 ultrasound guided HIFU placental vascular occlusion were encouraging. 
 
176 The main impact on maternal physiology was a modest fall in uterine artery blood flow 
 
177 during the treatment phase of the experimental protocol in both HIFU and sham exposure series. 
 
178 The only experimental feature related temporally to this fall in uterine blood flow was the uterine 
 
179 handling needed to alter uterine position in order to optimise the acoustic window during the 
 
180 treatment phase. This was necessary to optimise the path for the ultrasound beam to follow in 
 
181 order to produce vascular occlusion in the targeted placentomes. The effect of direct 
 
182 intraoperative uterine contact and handling on fetal wellbeing and physiology has not previously 
 
183 been reported. An acute, anaesthetic-related reduction in uterine artery blood flow secondary to 
 
184 maternal bradycardia and arterial hypotension has been linked to isoflurane usage (25-31), 
 
185 however, this response is time-dependent, and all parameters recovered to baseline within 120 
 
186 minutes of start of anaesthesia in these studies (25, 26). The maternal and fetal cardiovascular 
 
187 parameters in our study were within normal ranges at the start of the experimental protocol (start 
 
188 of baseline) as would be expected based on this previously published work, and isoflurane 
 
189 delivery remained stable throughout the experimental protocol. It is thus unlikely to account for 
 
190 the fall in uterine artery blood flow observed here. Maternal heart rate, arterial blood pressure 
 
191 remained stable through the experimental procedure, so the primary cause of reduced flow in the 
 
 
 
 
 
 
 
 
192 branch of the uterine artery blood flow in this setting may be the increased resistance in the 
 
193 uterine artery secondary to local vasospasm, rather than autoregulation due to the system-wide 
 
194 maternal cardiovascular alterations which have been reported under anaesthesia (32). 
 
195 Fetal peripheral vasoconstriction, although classically understood as part of the fetal brain 
 
196 sparing response to acute hypoxia (33), may also result from fetal acidosis rather than fetal 
 
197 hypoxia (34), primarily mediated by the sympathetic nervous response and maintained by 
 
198 endocrine mediated fetal stress responses (35). Peripheral vasoconstriction has been described in 
 
199 sheep fetuses as a response to reduced uterine blood flow in the absence of fetal hypoxia (36). 
 
200 Isoflurane sedation does not alter the capacity of fetal sheep to redistribute cerebral and systemic 
 
201 blood flow in response to reduced utero-placental flow or the development of acidosis (29). 
 
202 Accordingly, fetal peripheral vasoconstriction responses of the same magnitude were observed in 
 
203 both groups in response to the reduction in uterine artery blood flow that persisted beyond its 
 
204 normalisation in the recovery period. It is important to note that these responses were not 
 
205 worsened by the addition of HIFU placental vascular occlusion, and there was no corresponding 
 
206 increase in carotid blood flow during this period to suggest cerebral vasodilation (33, 37). The 
 
207 cerebral vasodilation aspect of the fetal brain sparing response to acute hypoxia is under 
 
208 paracrine, rather than systemic, control (33). Given that the delivery of oxygen and glucose to 
 
209 the fetal brain was preserved within normal limits for the duration of all experiments, hypoxia- 
 
210 induced cerebral vasodilatation would not be expected. Therefore, the increase in the ratio of the 
 
211 carotid to femoral blood flow in the fetus is secondary to the fall in femoral blood flow, most 
 
212 likely as a result of increased sympathetic outflow in response to the uterine vasospasm, rather 
 
213 than being representative of cerebral vasodilation and peripheral vasoconstriction in response to 
 
214 acute fetal hypoxia (37).  
 
 
 
 
 
 
 
 
215 While fetal oxygenation remained within normal limits for the duration of the procedure, 
 
216 there was a gradual reduction in the fetal PaO2, the saturation of oxy-haemoglobin, and delivery 
 
217 of oxygen to the brain between the baseline and recovery periods. These changes were not 
 
218 different between HIFU and sham groups and are more likely to represent fetal deterioration 
 
219 under anaesthetic than an effect of HIFU exposures. Mechanical ventilation was used to 
 
220 maintain the ewes in an isocapnic state despite the need for periods of breath holding; however a 
 
221 mixed respiratory and metabolic fetal acidosis still developed. Placental transfer of oxygen relies 
 
222 on the double Bohr effect, where elimination of carbon dioxide (CO2) from the fetal circulation 
 
223 drives maternal oxy-haemoglobin disassociation and increases the affinity of fetal haemoglobin 
 
224 for the oxygen. Anything that reduces fetal elimination of CO2, resulting in a fetal respiratory 
 
225 acidosis, paradoxically reduces the availability of maternal oxygen at the placental interface. A 
 
226 progressive fetal respiratory acidosis and falling PaO2 has been reported in the anaesthetised fetus 
 
227 regardless of concomitant operative procedures or fetal challenges (25, 26), and the PaCO2 at the 
 
228 end of our recovery period is comparable to other published values for this duration of isoflurane 
 
229 anaesthesia. We suggest that these changes in fetal pH are what underlie the trend to reduced 
 
230 oxygenation seen in our results. 
 
231 Carbon dioxide is generated by the fetus at a steady rate and is eliminated from the fetal 
 
232 circulation by diffusion across the placenta.(39) Elevated maternal PaCO2 causes steady state 
 
233 equilibration (Fick’s first principle) to reset to a higher baseline, eliminating less CO2 from the 
 
234 fetus. (39) While there was no increase in maternal PaCO2 observed during the experimental 
 
235 protocol, the maternal levels at baseline were above the normal range of a non-anaesthetised 
 
236 sheep. Ventilating sheep in the recumbent position and their increased alveolar dead space  
 
 
 
 
 
 
 
 
237 compared to humans make CO2 elimination less effective from the ovine lungs under anaesthesia 
 
238 (40-42) resulting in a mild maternal respiratory acidosis. 
 
239 The placental exchange rate of CO2 is also aeffected by the supra-physiological PaO2 in 
 
240 the mother and fetus. The Haldane effect describes the increased capacity of deoxygenated 
 
241 haemoglobin to buffer CO2 compared to oxygenated haemoglobin(43), and has been calculated 
 
242 to account for 46% of placental CO2 exchange.(39) The artificially elevated levels of oxygenated 
 
243 haemoglobin in both mother and fetus reduce the magnitude of the Haldane effect in this setting, 
 
244 and so further reduce the fetal elimination of CO2. CO2 diffusion across the placenta is limited 
 
245 by uterine blood flow(40) as it is highly soluble(43) so the additive effect of reduced uterine 
 
246 artery blood flow during the period of uterine manipulation accelerates the increase in fetal CO2 
 
247 accumulation. Decreases in fetal pH in our results are augmented by the fetal peripheral 
 
248 vasoconstriction observed: lactate is a product of anaerobic respiration and is produced in greater 
 
249 quantities by the under-perfused fetal tissues during peripheral vasoconstriction, particularly the 
 
250 muscle bulk of the hind limbs, and was seen to increase by the recovery period of the 
 
251 experiment, contributing to a mixed respiratory and metabolic acidosis (44). 
 
252 Collectively, these findings suggest an appropriate fetal defence response allowing 
 
253 compensation for a non-hypoxic challenge, rather than fetal distress resulting from HIFU. Given 
 
254 that HIFU is already in limited use in human pregnancy for treatment of TRAP sequence (3) 
 
255 these findings already have relevance to clinical obstetrics. It should be noted that these were 
 
256 healthy fetuses and that the effects on a fetus compromised by TTTS may be different. 
 
257 However, one aim of developing a non-invasive method to divide fetal circulations is to reduce 
 
258 the risks associated with the invasive nature of current therapies and to allow earlier intervention 
 
259 before such fetal compromise occurs.  
 
 
 
 
 
 
 
 
260 This study has demonstrated that placental vessels can be identified and targeted for 
 
261 HIFU ablation using colour Doppler ultrasound in the sheep. Non-invasive colour flow Doppler 
 
262 ultrasound improves the accuracy of HIFU targeting when compared to surgical exposure of 
 
263 visual identification of blood vessels (45). Targeting accuracy worse than 3 mm (46) can lead to 
 
264 failed vascular occlusion and injury to adjacent structures such as bowel (47, 48), nerves (49) or 
 
265 other vessels (50). Our treatment protocol, which places a linear track of 4-7 exposures across 
 
266 each vessel, involves a 6-12 mm linear movement of the automated gantry across the intended 
 
267 target and should be tolerant of a small degree of inaccuracy in targeting placental vessels. 
 
268 Placental vessels can be readily identified by Doppler ultrasound in sheep, and Doppler 
 
269 velocimetry correlates well with absolute flows measured invasively in these vessels (51, 52). 
 
270 Arterio-venous anastomoses in human monochorionic placentae have been successfully 
 
271 identified using colour and pulsed wave Doppler, with sensitivity of between 25-50% when 
 
272 compared to placental injection studies (54-56). In all cases, identification was easier with an 
 
273 anterior placenta, which is a more accessible target for HIFU exposures than a posterior placenta 
 
274 due to limitations of the fixed focal of any given HIFU transducer. 
 
275 The treatment protocol used shows that HIFU can consistently (93.3%) ablate in vivo 
 
276 placental vasculature blood flow in a pregnant sheep model, in vessels with clinically relevant 
 
277 diameters. While the protocol used did not achieve occlusion in every target, it is a strength of 
 
278 our technique that treatment success and failure can be assessed in real-time by the same 
 
279 modality (colour Doppler) used to target HIFU, and residual anastomoses may be suitable for 
 
280 immediate retreatment. Residual anastomoses are identified by colour Doppler imaging in 15- 
 
281 30% of cases following laser therapy (16) and may lead to recurrent disease with a worse overall 
 
282 prognosis (17) or a threefold increased incidence of a related condition, TAPS (13). Residual  
 
 
 
 
 
 
 
 
283 anastomoses may not be identified during laser treatment and would require a further invasive 
 
284 treatment to resolve, which is currently not recommended. Recently, fetoscopic laser has 
 
285 changed from selective coagulation of vessels where they crossed the “vascular equator” to 
 
286 bipartition of the placenta. Here, additional laser ablation of placental tissue is used to join the 
 
287 sites where vessels have been coagulated and create a physical separation between the twins’ 
 
288 circulations. This does improve neonatal survival and decreases rates of recurrence and TAPS, 
 
289 however it is associated with an 11.5% double twin loss rate, typically related to the invasive 
 
290 nature of fetoscopic laser (57). Although the anatomy of the sheep placenta lends itself to 
 
291 selective coagulation of vessels as the tissue is discontinuous, the automated gantry is capable of 
 
292 placement of exposures to form a confluent line of tissue destruction along a predetermined 
 
293 track, such as would be required for bipartition of the placenta, making either approach feasible. 
 
294 HIFU vascular occlusion typically requires higher levels of energy than ablation of soft 
 
295 tissue (58), and carries with it the potential complications of vessel rupture and haemorrhage, 
 
296 attributed to rapid changes in tissue pressure (47, 49, 59) or accumulation of excessive thermal 
 
297 energy in the vessel wall (60-62). This presents the possibility that the levels of energy required 
 
298 to occlude vessels may also cause vessel wall rupture. In our optimisation studies, ultrasound 
 
299 exposure intensities higher than used in this study did produce vessel haemorrhage (63) and 
 
300 maximum thresholds were applied, leading to the optimised protocol presented here. These 
 
301 safeguards meant that the single incidence of vessel wall rupture observed in this study was 
 
302 associated with non-movement of the gantry, resulting in over-exposure of a single region of the 
 
303 vessel wall. This happened only after 4 repeated exposures in the same location, suggesting a 
 
304 large safety margin in the upper dose threshold. By limiting the size of the target volume, and so 
 
305 the total dose delivered to the tissue, our protocol is able to successfully and consistently occlude  
306 placental vasculature in this setting, without crossing the threshold at which vascular rupture and 
 
307 haemorrhage occurs. Larger vessels are typically protected from rupture by their thicker walls 
 
308 and higher flow with greater cooling effect (64); one of the treatment failures was an attempt to 
 
309 occlude a larger vessel, and while unsuccessful was not associated with vascular haemorrhage. 
 
310 Concerns have been expressed about repeat exposure of vessels leading to vascular rupture (60- 
 
311 62). In this study, only 2 treatments were repeated, limiting our scope to discuss the value and 
 
312 safety of retreatment. The first was successful, although tissue damage was seen to spread into 
 
313 the peripheries reaching the capsule of the placentome. This might be considered to have 
 
314 breached a theoretical “safety margin” designed to protect adjacent structures. Despite this 
 
315 limitation, there was no maternal, uterine or fetal damage or damage to adjacent placentomes. 
 
316 The second retreatment attempted to ablate flow in a case of vessel haemorrhage, and was not 
 
317 successful in either ablating flow or in resolving the vessel haemorrhage. This suggests that an 
 
318 additional protocol of HIFU treatment from the one currently used should be applied for the case 
 
319 of inadvertent vascular haemorrhage, and this will be a focus of future studies prior to human 
 
320 application. 
 
321 The energy levels required to occlude placental vasculature (table S2) also present the 
 
322 possibility of pre-focal (maternal skin, abdominal fat, uterus) and post-focal (fetus) damage to 
 
323 structures in the path of the ultrasound energy. Such damage is a property of the focused beam, 
 
324 and shorter focal lengths and higher intensities increase the risk. Although there were no such 
 
325 complications in this study, the range of intensities used is at the higher end of those reported to 
 
326 produce vascular occlusion (58) and so there is potential to reduce these energy levels in future 
 
327 applications. There is also the possibility of lateral thermal spread outside the intended focal 
 
328 zone, as with any energy source that heats tissue, although HIFU exposures of soft tissue  
329 typically produce sharply demarcated lesions (65). Again, there were no such complications in 
 
330 this study. There are without doubt important technical considerations with regard to appropriate 
 
331 case selection and careful treatment planning of HIFU exposures to minimise these risks. 
 
332 However, these should be balanced against the potential benefits to mother and fetus of avoiding 
 
333 fetoscopy. 
 
334 Other potential difficulties still remain to be addressed before a human treatment could be 
 
335 implemented. The protocol, transducer and control software used in these preliminary 
 
336 experiments are not yet optimised for use in human pregnancy, and the need for an adequate 
 
337 acoustic window following surgical instrumentation, meant that HIFU was applied directly 
 
338 through the uterine surface rather than through the maternal skin. Delivering HIFU energy truly 
 
339 non-invasively (through intact skin) to achieve vascular occlusion is an essential challenge still 
 
340 to be met and will need to be the subject of future experimental studies either in sheep or other 
 
341 large animal model with a haemochorial placenta. As previously discussed, placental vascular 
 
342 anastomoses can be detected non-invasively by colour Doppler, and as demonstrated in our 
 
343 results colour Doppler is an appropriate targeting and treatment monitoring modality for HIFU 
 
344 exposures. The work of Okai et al (3) demonstrates that adequate HIFU energy can be delivered 
 
345 using a transdermal approach into the intrauterine space to ablate soft tissue at the cord insertion 
 
346 in human pregnancy, demonstrating the feasibility of our intended work. 
 
347 Another key feature of translating these techniques to human pregnancy will involve 
 
348 greater understanding of the mechanisms by which vascular occlusion is produced in this 
 
349 protocol, to allow customisation of any potential treatment system for human pregnancy to best 
 
350 exploit them. HIFU can interact with blood vessels to produce vascular occlusion by thermal 
 
351 mechanisms (58). Tissue heating can cause shrinkage of vessel walls (66), narrowing of vessel  
352 lumen (67), and/or fusion of the walls in a closed position (68). HIFU can also damage the 
 
353 vascular endothelium, producing occlusive thrombus that leads to permanent obliteration of the 
 
354 vessel through chronic inflammatory processes (69, 70). The methods used to assess treatment 
 
355 success suggest that tissue heating is an important feature of achieving successful vascular 
 
356 occlusion in this model. Hyperechoic regions, as seen at the HIFU focus in our targets, are 
 
357 associated with bubble formation due to tissue water boiling (71). Development of hyperechoic 
 
358 regions during two or more successive exposures appeared to be a sensitive and specific marker 
 
359 of successful vascular occlusion, compared to the observation of structural change of the 
 
360 placentome, which was not a good indicator of vascular occlusion. Evidence of tissue heating 
 
361 was seen macroscopically where tissue pallor (suggestive of tissue denaturation) occurred in the 
 
362 central region of treated placentomes. Histologically, both shrinkage of vessel lumen and 
 
363 occlusion of vessel lumen with clot were observed. Together, these features suggest that 
 
364 achieving tissue heating within the placentome is an important process in achieving vascular 
 
365 occlusion. 
 
366 In summary, these initial feasibility studies demonstrate the utility of ultrasound-guided 
 
367 HIFU to target and safely occlude placental blood vessels in vivo with a 93% success rate. This 
 
368 raises the prospect of non-invasive HIFU treatment of TTTS, and other related conditions 
 
369 resulting from abnormal placental vasculature, such as twin reversed arterial perfusion (TRAP) 
 
370 sequence and TAPS in human pregnancy. 
 
371 
 
372 
373 Materials and Methods 
 
374 Study design: This animal study was designed to assess the efficacy, materno-fetal 
 
375 responses and safety of using high intensity focused ultrasound (HIFU) to non-invasively 
 
376 occlude placental vasculature compared to sham treatment in anaesthetised animals. A total of 
 
377 11 pregnant sheep were used in the study (5 HIFU treated, 6 sham controls) and there was no 
 
378 randomisation or blinding. The study was powered to detect a difference in means of ≥ 2.5 at α = 
 
379 0.05 with a power of 80%, based on past published data of chronically instrumented sheep 
 
380 fetuses. The primary efficacy endpoint was achieving vascular occlusion; the primary safety 
 
381 endpoints were detection of uterine and fetal burns or placental haemorrhage. Maternal and fetal 
 
382 responses were measured through cardiovascular, acid-base and metabolic criteria. All 
 
383 procedures were performed in accordance with the UK Animals (Scientific Procedures) Act 1986 
 
384 and were approved by the Ethical Review Committee of the University of Cambridge. 
 
385 Surgical preparation: Eleven pregnant Welsh mountain sheep with singleton fetuses at 
 
386 116±2 days gestation (term ~147 days) were used. Animals were fasted for 24 hours prior to 
 
387 operation. Anaesthesia was induced with alfaxalone 3mg/kg (Alfaxan©, Jurox) and maintained 
 
388 with isoflurane (1.5-2.5% in 4:1 O2:N2O). Maternal oxygen saturation and end-tidal carbon 
 
389 dioxide (EtCO2) was monitored non-invasively; EtCO2 was maintained at <6%. The ewe was 
 
390 maintained in left lateral tilt. A midline abdominal incision was made and hysterotomy 
 
391 performed for instrumentation of the fetus. Fetal arterial catheters were introduced into the fetal 
 
392 carotid and femoral arteries, and advanced into the ascending and descending aorta respectively 
 
393 (37). A third catheter was placed in the amniotic fluid to provide a reference for “zero pressure”. 
 
394 Time-transit flow probes were placed around the contralateral fetal carotid and femoral arteries 
 
395 (2mm aperture, R-series, Transonic Systems Inc.) and on a main branch of the maternal uterine  
396 artery at the level of the cervix (4mm aperture, S-series, Transonic Systems Inc.). An arterial 
 
397 catheter was advanced into the maternal descending aorta via the femoral artery. The 
 
398 hysterotomy incisions were closed but the rectus sheath remained open to allow direct access for 
 
399 the HIFU probe to the uterine surface. 
 
400 Experimental protocol: Arterial blood pressures and flows were continuously 
 
401 monitored using the customised Cambridge Data Acquisition System (72).  Data were converted 
 
402 into absolute values and recorded for offline analysis (sampling rate of 500 kHz, IDEEQ, 
 
403 Maastricht Instruments). Mean values for sequential 1 minute epochs “minute means” were 
 
404 generated for cardiovascular data(Labchart 7 Pro, AD Instruments Ltd.). The experimental 
 
405 protocol was performed within 30 minutes of completion of surgery while the animal remained 
 
406 under anaesthesia. It was divided into: (i) a baseline period of 30 minutes during which the 
 
407 uterus was not manipulated and a static water-bag containing approximately 3 L of degassed 
 
408 water and the diagnostic and therapeutic transducers was in contact with the uterine surface. 
 
409 Placental vasculature was mapped using B Mode and colour Doppler ultrasound imaging (P10-4, 
 
410 Z. One Zonare or P10-4 Toshiba Powervision 7000); (ii) 30 minutes of HIFU exposure/sham 
 
411 exposure of placental vasculature (a total of 6 placentomes were targeted per animal with a 
 
412 single vessel targeted per placentome). This phase included gentle manipulation of the uterus to 
 
413 optimise the acoustic window; (iii) a 30 minute recovery period, after which the animals were 
 
414 euthanized by terminal anaesthesia. Blood samples were taken from the maternal femoral artery, 
 
415 the fetal femoral and carotid arteries at the start of baseline (-30 min), the start, midpoint and end 
 
416 of HIFU/sham exposures and at the end of the recovery phase (fig. S1). We measured acid-base 
 
417 status, PaO2 and PaCO2 (ABL5 Blood Gas Analyser, Radiometer); haemoglobin, haematocrit and  
418 oxygen saturation of the blood (ABL80 Flex, Radiometer); blood glucose and lactate (YSI 2300 
 
419 Stat Plus, Yellow Springs Instruments). 
 
420 
 
421 HIFU Protocol: HIFU was applied directly through the uterine surface, through the 
 
422 degassed water filled bag suspended from an arm on a positioning gantry. The Sonic Concepts 
 
423 H148MR transducer used (frequency 1.66 MHz, 64 mm diameter, 63 mm focal length, 19 mm 
 
424 central aperture for ultrasound imaging, focal diameter 1.2 mm, focal length 8.9 mm) was held in 
 
425 position within the water bag on an automated 3D positioning gantry (fig. 5a). A laptop 
 
426 computer was used to run a graphical user interface (MATLAB R2013a, Mathworks) to control 
 
427 and log the automated gantry position, signal generator settings timing of exposures. A single 
 
428 line of HIFU exposures was made, using the motorised gantry, across the target vessel in the 
 
429 central region of each placentome (fig. 5b), identified using a P 10-4 Zonare ultrasound probe 
 
430 centrally mounted behind the HIFU transducer. Exposure conditions were: 4-7 exposures of 5 s 
 
431 duration, spaced 5 s and 2 mm apart at an estimated in situ ISPTA of 4000 to 5700 W.cm
-2
 (table 
 
432 S2) based on a HIFU protocol we optimised previously and described elsewhere (63). Tissue 
 
433 responses such as hyperecho and structural change were recorded (3 s clips) using tissue 
 
434 harmonic imaging (8.0 MHz B Mode) during exposures for offline analysis. Placental 
 
435 vasculature was assessed and still images recorded before and immediately after HIFU exposure 
 
436 using colour Doppler in the same 3D position, controlled by the automated gantry. Treatment 
 
437 success was when no flow was detectable on colour Doppler post treatment using the lowest 
 
438 velocity scale setting and pre-gain settings. If occlusion was incomplete, re-ablation of the same 
 
439 target using the same protocol was attempted once, if judged safe to do so, before exposure of a 
 
440 subsequent target. Mechanical ventilation pauses of up to 90 s were required during HIFU 
441 exposure series as respiratory movement could lead to mistargeting. Ventilation was planned to 
 
442 be resumed before the end of a HIFU exposure series if maternal EtCO2 rose to >8% or SpO2 fell 
 
443 to <94%, although this did not occur. 
 
444 Post mortem and Histology: Green dye was injected under ultrasound guidance into 
 
445 tissue adjacent to exposed placentomes for post-mortem identification. Animals were sacrificed 
 
446 using pentobarbitone sodium 120mg/kg by rapid intravenous injection (Pentoject®, Animalcare) 
 
447 at the completion of the HIFU protocol (within 4 hours of its start) and a post mortem was 
 
448 conducted to identify exposed placentomes, or iatrogenic harm to mother (examination of 
 
449 adjacent organs) or fetus (external examination). All treated, and a smaller number of control 
 
450 placentomes were dissected, examined for gross pathological changes, photographed and 
 
451 immersion fixed in 4% formaldehyde for 5 days before embedding in paraffin wax. Ten 
 
452 micrometre sections were stained with Haematoxylin and Eosin. 
 
453 Statistical analyses: Minute means and absolute values from blood sampling are 
 
454 expressed as mean ± standard error of the mean (SEM). Summary measure analysis (area under 
 
455 the curve) was applied to the cardiovascular data for statistical analysis (73). Normality was 
 
456 assessed using the Shapiro Wilks test, and a repeated measure, two-way ANOVA (variables time 
 
457 and treatment group) for parametric values and Kruskall-Wallis test for non-parametric values 
 
458 was applied. In the repeated measure (RM) ANOVA, if a significant interaction was 
 
459 demonstrated for time or treatment, post hoc Tukey’s or Sidak’s test was applied. Statistical 
 
460 significance was accepted when p <0.05.  
 
 462 List of Supplementary Materials: 
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464 Table S1: Summary of treatment outcomes 
 
465 Table S2: Summary of exposure conditions 
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656 Figure and table captions: 
 
657 Fig. 1. Colour Doppler and B-Mode ultrasound imaging of placental vascular ablation 
 
658 (A) Pre-treatment colour Doppler imaging of a placentome. The cursor marks the 
 
659 intended vascular target; (B) post-treatment colour Doppler imaging of the same 
 
660 placentome demonstrating “no flow” within the targeted vessel; (C) B-mode harmonic 
 
661 ultrasound imaging of hyperechoic region within the HIFU focal zone. 
 
662 
 
663 Fig. 2. Macroscopic and microscopic results of HIFU exposures 
 
664 (A) Tissue darkening, and; (B) Tissue pallor involving the central area of a bisected 
 
665 placentome; (C) H&E section (x2.5 magnification) of fetal vessels in control placentome; 
 
666 (D) H&E section (x2.5 magnification) of fetal vessels in HIFU exposed placentomes 
 
667 showing clot filled vessel lumen. 
 
668     
669 Figure 3: Maternal cardiovascular responses to HIFU / Sham placental vascular ablation  
670 Values represent mean values for each sequential minute ± SEM of percentage change  
671 from baseline during the baseline (-30-0 mins), HIFU (n=5) or sham (n=6) ablation of  
672 placental vasculature (dashed box; 0-30 mins) and recovery (30-60 mins). Black bar  
 
represents significant change from baseline. Significant differences: 
 
time vs. 
 
673 * p<0.05  
     
674 baseline, RM two way ANOVA with post hoc Tukey test. 
 
  
 
676    Figure 4: Fetal cardiovascular responses to HIFU / Sham placental vascular ablation 
  
 
 
 
 
 
 
677 Values represent mean values for each sequential minute ± SEM of percentage change 
 
678 from baseline during the baseline (-30-0 mins), HIFU (n=5) or sham (n=6) ablation of 
 
679 placental vasculature (dashed box; 0-30 mins) and recovery (30-60 mins) while under 
 
680 general anaesthesia. Black bar represents significant change from baseline. Significant 
 
681 differences: * p<0.05 time vs. baseline RM two way ANOVA with post hoc Tukey test. 
 
682 
 
683 Figure 5: Diagram of side view of equipment setup and HIFU exposure placement 
 
684 (A) Setup of the ring shaped HIFU transducer and central diagnostic ultrasound probe 
 
685 within a bag of degassed water; (B) placement of HIFU lesions in a linear track across the 
 
686 origin of the fetal vessels.   
 
 
 
 
 
 
 
 
 
Values represent mean ± SEM of fetal carotid arterial blood sampled at the start of the baseline 
period (-30 mins), the start, middle and end of the HIFU (n=5) or sham (n=6) exposure series (0, 
15, 30 mins) and the end of the recovery period (60 mins). Significant 
 692 
693 
 687 
694 
695    Table 2: Fetal arterial acid base and metabolic status 
Values represent mean ± SEM of maternal femoral arterial blood sampled at the start of 
the baseline period (-30 mins), the start, middle and end of the HIFU (n=5) or sham (n=6)
exposure series (0, 15, 30 mins) and the end of the recovery period (60 mins). Significant 
differences *p<0.05 effect of time vs. baseline; 
†
p<0.05 effect of treatment group, RM 
two-way ANOVA with post hoc Tukey and Sidak tests. 
690 
691 
688      Table 1: Maternal arterial acid base and metabolic status  
699 differences *p<0.05 effect of time vs. baseline, †p<0.05 effect of treatment group, RM 
 
700 two-way ANOVA with post hoc Tukey and Sidak tests. 
 
701 
 
702 Table 3: Fetal substrate delivery 
 
703 Values represent mean ± SEM of fetal carotid and femoral arterial blood sampled at the 
 
704 start of the baseline period (-30 mins), the start, middle and end of the HIFU (n=5) or 
 
705 sham (n=6) exposure series (0, 15, 30 mins) and the end of the recovery period (60 mins). 
 
706 Significant differences *p<0.05 effect of time vs. baseline, RM two-way ANOVA with 
 
707 post hoc Tukey test. 
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